Mainz Biomed (NASDAQ MYNZ), a company that specializes in developing molecular genetic diagnostic solutions for life-threatening conditions, has created ColoAlert, an innovative product that addresses the need for easier and more accessible cancer screenings for quick detection and treatment of colorectal cancer. This non-invasive and user-friendly test aims to make colorectal cancer screening fast, simple and precise. The test is the first DNA-based screening test for colorectal cancer in Europe.
